GlobeNewswire by notified

Juniper Systems Limited Releases New Geode GNS3 GNSS Receiver

Share

The rugged Geode GNS3 GNSS Receiver from Juniper Systems Limited is available in single- and multi-frequency antenna configurations, delivering a scalable platform for greater accuracy needs

BIRMINGHAM, United Kingdom, May 04, 2022 (GLOBE NEWSWIRE) -- Today Juniper Systems Limited, a manufacturer of rugged handheld computers and GNSS receivers, launched its rugged Geode™ GNS3 GNSS Receiver, delivering real-time data collection with sub-metre, sub-foot, and decimetre accuracy options. The Geode GNS3 GNSS Receiver is now available worldwide.

This all-new GNSS receiver offers a scalable platform so users can obtain the level of accuracy they need now, with the option to increase accuracy in the future. Plus it’s available without the huge price tag or complexity of other precision receivers.

‘This new Geode offers expanded accuracy options to our users’, said Mr John Florio, Geode product manager at Juniper Systems, Inc. ‘We set out to deliver a product that is scalable to our users’ needs. The GNS3 allows users to obtain a receiver that fits their accuracy needs at the moment, while allowing them to obtain greater accuracy through subscriptions when that need arises’.

Available in both single-frequency and upgradable multi-frequency antenna configurations, users have the level of accuracy needed to adapt to a job’s requirements. The Geode GNS3S (single frequency) offers precise sub-metre accuracy with a single frequency antenna. The Geode GNS3M, with a multi-frequency antenna, allows for scalable accuracy, including support for all constellations on L1, L2, and L5 frequencies.

Multi-frequency signal tracking, together with Atlas L-Band correction subscriptions, provide accuracy to the decimetre level. As with previous Geode receivers, SBAS corrections are available for sub-metre accuracy in certain regions. Both models also support local differential GNSS RTK/CORS network corrections through the Geode Connect NTRIP Client.

‘The Geode is such a flexible device; we designed it to be used across a broad spectrum of industries’, said Mr Simon Bowe, managing director of Juniper Systems Limited. ‘Atlas correction capability and scalable accuracy allow the Geode to be used in markets such as railway maintenance, asset tracking, water utility locating, agriculture and irrigation mapping, forest services, environmental sciences, wildlife management, and other remote location mapping projects where other correction services are not available, or which require a higher degree of accuracy’.

Like all products from Juniper Systems, rugged features are inherent to the Geode GNS3 design. Tested against U.S. standard MIL-STD-810G, it withstands drops, shock, vibration and temperature extremes. The enclosure is rated IP68, sealed against moisture and dust ingress.

The Geode GNS3 continues to offer flexible connectivity and can be used with devices running on Microsoft® Windows, Android™, or Apple® operating systems. Its all-in-one design makes it compact for easy portability. It features only a single button for easy use. The USB-C port provides for data transfer and fast charging, and an antenna port allows use of an external antenna, if desired.

Geode GNS3 single- and multi-frequency receivers are available now through Juniper Systems Limited and our reseller partners. Visit our Geode product page for more information.

About Juniper Systems Limited

Based out of Logan, Utah, USA, and Birmingham, UK, Juniper Systems (https://junipersys.com) is a world leader in the design and manufacture of ultra-rugged handheld computers, GNSS receivers, and mapping software, creating field data collection solutions for extreme environments. Since 1993, professionals have utilised Juniper Systems’ innovative mobile technology in the railway, geomatics, industrial, environmental sciences, mining, military, utilities and public services markets.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d5dbf957-71a2-4246-9dfa-0a6d460a3d80

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Nextensa NV/SA : Shares repurchase26.5.2022 17:40:00 CEST | Press release

PRESS RELEASE REGULATED INFORMATION Brussels, 26 May 2022 – 5.40 PM CEST Nextensa NV/SA : Shares repurchase In accordance with article 8:4 of the Royal Decree of 29 April 2019 in execution of the Belgian Code of Companies and Associations, Nextensa announces that in the period between May 19, 2022 and May 25, 2022 included it has repurchased 1,889 treasury shares on Euronext Brussels as part of its announced share buy-back program1. The shares were repurchased at an average price (rounded) of € 68.00 per share. This share repurchase transaction was carried out to cover the purchase plans for the benefit of the executive management of Nextensa, and this within the limits set down in the (renewed) share repurchase authorization as granted by the extraordinary general meeting of shareholders on 19 July 2021. Detailed operations per day DateNumber of sharesAverage price (€)Minimum price (€)Maximum price (€)Total price (€)19/05/202245067.8667.7067.9030,535.0020/05/202245068.4868.4068.9030,8

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons26.5.2022 15:00:33 CEST | Press release

26 May 2022 VOLTA FINANCE LIMITED (VTA / VTAS) Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons On 24 May 2022, Mr Paul Meader, Director and Chairman of the Board of the Company, transferred 3,130 shares in the Company to his wife, Sarah Kingwell. Following this transaction the total interests in the Company of Mr Meader (and his Closely Associated Persons) remain unchanged at 48,175 shares, representing 0.13% of the issued shares in the Company. The below notification, made in accordance with the requirements of article 19.3 of the EU Market Abuse Regulation, gives further details: 1 Details of the person discharging managerial responsibilities / person closely associated a) Name 1) Paul Meader 2) Sarah Kingwell 2 Reason for the notification a) Position/status 1) Director and Chairman 2) PCA b) Initial notification /Amendment Initial Notification 3 Details of the issuer, emission allowance market participant, auction platfor

Mandalay Resources Corporation tillkännager resultatet av årsstämman26.5.2022 14:41:34 CEST | Pressemelding

TORONTO, May 26, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) har nöjet att tillkännage resultaten från årsstämman (”mötet”) som hölls virtuellt idag. Alla resolutioner som presenterades vid mötet godkändes av aktieägarna och röstningen som skedde genom fullmakt motsvarade 67,63 % av de totalt utestående aktierna på avstämningsdagen. Val av styrelseledamöter Antalet styrelseledamöter var oförändrat med sju ledamöter och var och en av de sju nominerade som fanns listade i bolagsledningens informationsutskick från den 14 april 2022 återvaldes till bolagsstyrelsen. Abraham Jonker fortsätter som oberoende samordnande ledamot och Bradford Mills fortsätter som ordförande. Resultaten av rösterna genom ombud anges nedan. ResolutionVotes Cast by Proxy For% ForVotes Cast by Proxy Withheld% WithheldBradford A. Mills61,552,12099.95329,1930.047Abraham Jonker61,551,31399.95130,0000.049Amy Freedman61,547,53899.94533,7750.055Dominic Duff

Interim results for the period ended March 31, 202226.5.2022 13:30:47 CEST | Press release

Golar LNG Limited ("Golar" or "the Company") reports Q1 2022 ("Q1") Net income of $345.2 million.Adjusted EBITDA1 of $93.4 million for the quarter inclusive of FLNG Hilli, Golar Arctic and Golar Tundra but excluding the 8 TFDE vessels and management companies sold to Cool Company Ltd. ("CoolCo"). Sold 6.2 million New Fortress Energy Inc. ("NFE") shares in Q2 2022 ("Q2") realizing net cash proceeds of $253 million. Golar now owns 12.4 millionNFE shares following the sale.Q1 Total Golar Cash and Listed Securities1 position increased by $0.4 billion to $1.3 billion. Golar's share of Contractual Debt1 decreased by $0.5 billion to $1.7 billion in Q1 and a further $0.5 billion in Q2 after sale of remaining carriers to CoolCo in April.Agreed to sell the steam turbine carrier Golar Arctic as a converted FSRU to Italy's Snam for 269 million Euros ($288 million). Strong progress made on opportunities for FSRU Golar Tundra and on pipeline of FLNG projects. Shipping spin-off: A key focus for Q1 wa

Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery26.5.2022 13:30:00 CEST | Press release

– Company announces rebranding to Dante Genomics to reflect its broader global efforts – NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, highlights significant progress made in its drug discovery development program with six drug candidates currently in the Company’s pipeline, applying Dante’s internal siRNA and mRNA technology to rare and common diseases. Since the company’s foundation, Dante has invested in a robust R&D program with the goal to create end-to-end solutions from diagnosis to therapy. Dante’s program began with a focus on rare disease, in response to a diagnosis of a patient with a rare disease for which there were no treatment therapies. Dante’s pipeline has evolved across multiple disease areas with four drug programs in full internal development and two in co-development to achieve validation and partner externally on clinical trials and commercialization. “Personalized medicine needs personalized data, a